130 likes | 148 Views
Comprehensive Pre-clinical and Clinical CRO. Theragene Overview. Company founded in 2001, San Diego, CA Originally focused on vector development for the gene therapy industry Full Service CRO Pre-clinical and Clinical Development Sister company, Theragene Pharmaceuticals.
E N D
Theragene Overview • Company founded in 2001, San Diego, CA • Originally focused on vector development for the gene therapy industry • Full Service CRO • Pre-clinical and Clinical Development • Sister company, Theragene Pharmaceuticals
Pre-clinical Development • Pre-clinical Research (CRO) • In Vitro ADMET • Bioanalysis • Bioequivalence/Bioavailability Services (Phase 1) • Toxicology/Pharmacology Services • Pharmacokinetics • Pharmaceutical Analysis
Clinical Development • Clinical Research (CRO) • Regulatory Affairs • Project Management • Site Management • Medical Affairs • Data Management • Statistical Analysis
Theragene Management • Jon Berglin, President & CEO • Charles Zhang, PhD, COO • John Giammona, PhD, SVP-Operations and BD • Steve Davis, Esq. VP-General Counsel • Warren Pleskow, MD, Chief Medical Advisor
Theragene Facilities • San Diego, CA • Beijing, China
Theragene Initiatives • CRO Growth • United States • China • Europe • South America • Joint Ventures • Phase 1 Facilities Established
Theragene Collaborators • Pre-Clinical Services • iPhase Pharma Services, Beijing, China • Zhongshan Pharma SS, Guangzhou, China • Clinical Services • Conventus • Vertexx Data Designs • Comprehensive Clinical Development • Pacific Pharma Services
Theragene Collaborators • Key Academic Collaborators • University of California, San Diego (UCSD) • University of California, Los Angeles (UCLA) • Salk Institute for Biological Studies • The Scripps Research Institute (TSRI) • City of Hope (Duarte, CA) • John Wayne Cancer Institute
Key Customers • Cosmo Bioscience, Inc. • Theragene Pharmaceuticals, Inc. • Eclipse Therapeutics, Inc. • PersImmune, Inc. • The Scripps Research Institute (TSRI)
Theragene Financials • 2011 Projected Revenue: • 2011 Projected EBITDA: • Same Store Growth Projections • Revenue from Chinese Operations
Theragene’s Growth Strategy • Same Store Growth • Emerging Markets • Phase 1 Facilities • Joint Ventures/Collaborations • Strong Marketing Campaign
Conclusions • Full Service Pre-clinical and Clinical CRO • Worldwide growth within 2011 • Increased Joint Ventures/Collaborations • Exponential Financial Growth over the next 5 years • Established as a leader in bridging studies between US and China